NZ535284A - Microparticles of glycopyrrolate for the treatment of respiratory diseases - Google Patents

Microparticles of glycopyrrolate for the treatment of respiratory diseases

Info

Publication number
NZ535284A
NZ535284A NZ535284A NZ53528401A NZ535284A NZ 535284 A NZ535284 A NZ 535284A NZ 535284 A NZ535284 A NZ 535284A NZ 53528401 A NZ53528401 A NZ 53528401A NZ 535284 A NZ535284 A NZ 535284A
Authority
NZ
New Zealand
Prior art keywords
glycopyrrolates
formulation
treatment
inhalation
microparticles
Prior art date
Application number
NZ535284A
Other languages
English (en)
Inventor
Robin Mark Bannister
Andrew John Mcglashan Richards
Julian Clive Gilbert
David A V Morton
John Staniforth
Original Assignee
Arakis Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=9889490&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=NZ535284(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Arakis Ltd filed Critical Arakis Ltd
Publication of NZ535284A publication Critical patent/NZ535284A/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/0075—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a dry powder inhaler [DPI], e.g. comprising micronized drug mixed with lactose carrier particles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/46—8-Azabicyclo [3.2.1] octane; Derivatives thereof, e.g. atropine, cocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/145—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/08—Bronchodilators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Pulmonology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Otolaryngology (AREA)
  • Emergency Medicine (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Detergent Compositions (AREA)
  • Saccharide Compounds (AREA)
  • Steroid Compounds (AREA)
NZ535284A 2000-04-07 2001-04-09 Microparticles of glycopyrrolate for the treatment of respiratory diseases NZ535284A (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB0008660.3A GB0008660D0 (en) 2000-04-07 2000-04-07 The treatment of respiratory diseases

Publications (1)

Publication Number Publication Date
NZ535284A true NZ535284A (en) 2006-04-28

Family

ID=9889490

Family Applications (2)

Application Number Title Priority Date Filing Date
NZ535284A NZ535284A (en) 2000-04-07 2001-04-09 Microparticles of glycopyrrolate for the treatment of respiratory diseases
NZ521476A NZ521476A (en) 2000-04-07 2001-04-09 Microparticles of glycopyrrolate for the treatment of respiratory diseases

Family Applications After (1)

Application Number Title Priority Date Filing Date
NZ521476A NZ521476A (en) 2000-04-07 2001-04-09 Microparticles of glycopyrrolate for the treatment of respiratory diseases

Country Status (25)

Country Link
US (3) US7229607B2 (OSRAM)
EP (3) EP1267866B2 (OSRAM)
JP (1) JP5042426B2 (OSRAM)
CN (3) CN101181263B (OSRAM)
AT (1) ATE330585T2 (OSRAM)
AU (2) AU2004242450B2 (OSRAM)
BE (1) BE2013C023I2 (OSRAM)
BR (1) BR0109875A (OSRAM)
CA (1) CA2405705C (OSRAM)
CY (1) CY1105120T1 (OSRAM)
DE (1) DE60120936T3 (OSRAM)
DK (1) DK1267866T4 (OSRAM)
ES (2) ES2687751T3 (OSRAM)
GB (1) GB0008660D0 (OSRAM)
HK (1) HK1050846B (OSRAM)
HU (2) HU230958B1 (OSRAM)
IL (2) IL151791A0 (OSRAM)
LU (2) LU92166I2 (OSRAM)
MX (1) MXPA02009718A (OSRAM)
NO (3) NO336142B1 (OSRAM)
NZ (2) NZ535284A (OSRAM)
PL (1) PL364024A1 (OSRAM)
PT (1) PT1267866E (OSRAM)
WO (1) WO2001076575A2 (OSRAM)
ZA (1) ZA200207420B (OSRAM)

Families Citing this family (66)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0008660D0 (en) 2000-04-07 2000-05-31 Arakis Ltd The treatment of respiratory diseases
ES2708961T3 (es) 2000-11-30 2019-04-12 Vectura Ltd Composiciones farmacéuticas para inhalación
US8580306B2 (en) 2000-11-30 2013-11-12 Vectura Limited Particles for use in a pharmaceutical composition
CA2341952A1 (en) * 2001-03-23 2002-09-23 Universite Laval Nicotinic receptor agonists for the treatment of inflammatory pulmonary diseases
US20050130990A1 (en) * 2001-03-23 2005-06-16 Universite Laval Nicotinic receptor agonists for the treatment of inflammatory diseases
EP1389467B1 (en) 2001-05-23 2013-07-03 Mitsubishi Tanabe Pharma Corporation Therapeutic composition for the regenerative treatment of cartilage diseases
CN1520313A (zh) 2001-05-23 2004-08-11 ������ҩ��ʽ���� 一种加速骨折愈合的组合物
IL163843A0 (en) * 2002-03-01 2005-12-18 Chiesi Farma Spa Formoterol superfine formulation
US8039459B2 (en) 2004-07-15 2011-10-18 Universite Laval Nicotinic receptor agonists for the treatment of inflammatory diseases
US8557804B2 (en) 2002-03-25 2013-10-15 Universite Laval Nicotinic receptor agonists for the treatment of inflammatory diseases
US20040121003A1 (en) * 2002-12-19 2004-06-24 Acusphere, Inc. Methods for making pharmaceutical formulations comprising deagglomerated microparticles
CA2534352A1 (en) * 2003-08-08 2005-02-17 Arriva Pharmaceuticals, Inc. Methods of protein production in yeast
GB0327723D0 (en) * 2003-09-15 2003-12-31 Vectura Ltd Pharmaceutical compositions
SI1684719T1 (sl) * 2003-11-14 2012-07-31 Baxter Int Sestavki alfa antitripsina in postopki zdravljenja ob uporabi takih sestavkov
DK1713471T3 (da) 2004-02-06 2012-05-14 Meda Pharma Gmbh & Co Kg Kombination af anticholinergika og inhibitorer af phosphodiesterase type 4 til behandling af respiratoriske sygdomme
DE602005007708D1 (de) * 2004-02-06 2008-08-07 Meda Pharma Gmbh & Co Kg Neue kombination von anticholinergen und beta mimetika zur behanldung von atemwegserkrankungen
JP2007520509A (ja) * 2004-02-06 2007-07-26 メダ ファーマ ゲゼルシャフト ミット ベシュレンクテル ハフツング ウント コンパニー コマンディト ゲゼルシャフト 抗コリン薬による、又は抗ヒスタミン薬、ホスホジエステラーゼ４、又はコルチコステロイドとの組み合わせによる鼻炎治療薬
PL1713473T3 (pl) * 2004-02-06 2013-08-30 Meda Pharma Gmbh & Co Kg Kombinacja leków antycholinergicznych i glikokortykoidów do długotrwałego leczenia astmy i POChP
US20070185067A1 (en) * 2004-02-27 2007-08-09 Altana Pharma Ag Ciclesonide and glycopyrronium combination
EP1737499A4 (en) * 2004-03-09 2009-07-22 Arriva Pharmaceuticals Inc TREATMENT OF CHRONIC OBSTRUCTIVE LUNG DISEASE BY INHALATION OF LOW DOSES OF A PROTEASE HEMMER
GB0409703D0 (en) 2004-04-30 2004-06-02 Vectura Ltd Pharmaceutical compositions
GB0410398D0 (en) * 2004-05-10 2004-06-16 Arakis Ltd The treatment of respiratory disease
GB0410399D0 (en) * 2004-05-10 2004-06-16 Arakis Ltd The treatment of respiratory disease
GB0411056D0 (en) 2004-05-18 2004-06-23 Novartis Ag Organic compounds
WO2006003078A1 (en) * 2004-06-29 2006-01-12 Boehringer Ingelheim International Gmbh Medicaments for inhalation comprising steroids and an anticholinergic
EP1616567A1 (en) * 2004-07-16 2006-01-18 Boehringer Ingelheim Pharma GmbH & Co.KG Medicaments for inhalation comprising PDE IV inhibitors and glycopyrrolate salts
US9061027B2 (en) 2004-08-27 2015-06-23 Board Of Regents, The University Of Texas System Enhanced delivery of drug compositions to treat life threatening infections
US20070105768A1 (en) * 2004-11-10 2007-05-10 Rajiv Nayar Dry recombinant human alpha 1-antitrypsin formulation
GB0425758D0 (en) 2004-11-23 2004-12-22 Vectura Ltd Preparation of pharmaceutical compositions
US8623405B2 (en) * 2005-01-28 2014-01-07 Takeda Pharmaceutical Company Limited Finely divided composition containing poorly water soluble substance
HUE027076T2 (en) 2005-03-16 2016-08-29 Meda Pharma Gmbh & Co Kg Combination of anticholinergics and leukotriene receptor antagonists for the treatment of respiratory diseases
EP1861361A1 (en) * 2005-03-24 2007-12-05 Sosei R&D Ltd. Glycopyrronium salts and their therapeutic use
US20070148211A1 (en) * 2005-12-15 2007-06-28 Acusphere, Inc. Processes for making particle-based pharmaceutical formulations for oral administration
ES2389231T3 (es) 2005-12-21 2012-10-24 Meda Pharma Gmbh & Co. Kg Combinación de anticolinérgicos, glucocorticoides y agonistas de beta2 para el tratamiento de enfermedades inflamatorias
GB2434098A (en) * 2005-12-23 2007-07-18 Novartis Ag Process for the preparation of an inhalable dry powder formulation
US20090062326A1 (en) * 2006-03-17 2009-03-05 Spindel Eliot R M3 muscarinic receptor antagonists for treatment of m3 muscarinic receptor-expressing tumors
GB0613161D0 (en) 2006-06-30 2006-08-09 Novartis Ag Organic Compounds
CN101896165B (zh) * 2007-12-13 2013-07-17 诺瓦提斯公司 有机化合物
CA2708083C (en) * 2007-12-13 2016-06-28 Novartis Ag Organic compounds
US20100055045A1 (en) * 2008-02-26 2010-03-04 William Gerhart Method and system for the treatment of chronic obstructive pulmonary disease with nebulized anticholinergic administrations
US20090215734A1 (en) * 2008-02-26 2009-08-27 Elevation Pharmaceuticals, Inc. Method and system for the treatment of chronic obstructive pulmonary disease with nebulized anticholinergic administrations
EP4578502A3 (en) 2009-02-26 2025-10-08 Glaxo Group Limited Pharmaceutical formulations comprising 4-{(1 r)-2-[(6-{2-[(2,6-dichlorobenzyl)oxy]ethoxy}hexyl)amino]-1-hydroxyethyl}-2-(hydroxymethyl)phenol
US8815258B2 (en) 2009-05-29 2014-08-26 Pearl Therapeutics, Inc. Compositions, methods and systems for respiratory delivery of two or more active agents
KR20170070274A (ko) 2009-05-29 2017-06-21 펄 테라퓨틱스 인코포레이티드 지속형 무스카린 안타고니스트 및 지속형 ｂ₂아드레날린 수용체 아고니스트의 폐 전달용 조성물, 및 연관된 방법 및 시스템
GB0921075D0 (en) 2009-12-01 2010-01-13 Glaxo Group Ltd Novel combination of the therapeutic agents
RU2567040C2 (ru) 2009-12-23 2015-10-27 КЬЕЗИ ФАРМАЧЕУТИЧИ С.п.А. Аэрозольная препаративная форма для лечения по поводу хронического обструктивного легочного заболевания
EA027778B1 (ru) 2009-12-23 2017-08-31 КЬЕЗИ ФАРМАЧЕУТИЧИ С.п.А. Комбинированная терапия copd
SG181870A1 (en) 2009-12-23 2012-07-30 Chiesi Farma Spa Aerosol formulation for copd
EP2515853B1 (en) 2009-12-23 2014-03-19 Chiesi Farmaceutici S.p.A. Combination therapy for COPD
CA2812414C (en) * 2010-09-29 2020-09-22 Pulmatrix, Inc. Monovalent metal cation dry powders for inhalation
JOP20120023B1 (ar) * 2011-02-04 2022-03-14 Novartis Ag صياغات مساحيق جافة من جسيمات تحتوي على واحد أو اثنين من المواد الفعالة لعلاج امراض ممرات الهواء الانسدادية او الالتهابية
WO2013016754A1 (en) 2011-08-01 2013-02-07 Monash University Method and formulation for inhalation
US20150136130A1 (en) 2012-02-29 2015-05-21 Pulmatrix, Inc. Inhalable dry powders
JP6454323B2 (ja) 2013-03-15 2019-01-16 パール セラピューティクス，インコーポレイテッド 粒子状結晶性材料のコンディショニングのための方法及びシステム
KR20150135328A (ko) 2013-04-01 2015-12-02 풀매트릭스 인코퍼레이티드 티오트로피움 건조 분말
US9393202B2 (en) 2013-04-26 2016-07-19 Chiesi Farmaceutici S.P.A Particle size reduction of an antimuscarinic compound
US20160317391A1 (en) * 2013-12-17 2016-11-03 Merck Sharp & Dohme Corp. Media milling process for the manufacture of active pharmaceutical ingredients in propellants
KR101861117B1 (ko) 2013-12-30 2018-05-28 키에시 파르마슈티시 엣스. 피. 에이. 글리코피로니움 브로마이드 및 포모테롤 조합의 안정한 가압 에어로졸 용액 조성물
SG11201700536XA (en) 2014-09-09 2017-02-27 Vectura Ltd Formulation comprising glycopyrrolate, method and apparatus
AU2015316592B2 (en) * 2014-09-15 2020-04-02 Verona Pharma Plc Liquid inhalation formulation comprising RPL554
MA41378A (fr) * 2015-01-20 2017-11-28 Teva Branded Pharmaceutical Prod R & D Inc Inhalateur de poudre sèche comprenant du propionate de fluticasone et du xinafoate de salmétérol
US20160310410A1 (en) 2015-04-24 2016-10-27 Glenmark Specialty S.A. Pharmaceutical compositions comprising arformoterol and glycopyrronium
JP6910069B2 (ja) * 2015-06-15 2021-07-28 キューエーエーエム ファーマシューティカルズ，エルエルシー グリコピロニウム脂肪酸塩およびグリコピロニウム脂肪酸塩を作る方法
US9925168B2 (en) * 2016-01-22 2018-03-27 Chiesi Farmaceutici S.P.A. Preparation of micronized particles of an antimuscarinic compound by hydrodynamic cavitation
US10098837B2 (en) 2016-07-28 2018-10-16 Chiesi Farmaceutici S.P.A. Combination therapy for COPD
CN114502146A (zh) 2019-12-02 2022-05-13 奇斯药制品公司 用于加压定量吸入器的不锈钢罐

Family Cites Families (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3400197A (en) 1965-01-26 1968-09-03 Robins Co Inc A H Compressible sustained release pharmaceutical tablet lipid-colloidal silica gel matrix fragment granules
US5376386A (en) * 1990-01-24 1994-12-27 British Technology Group Limited Aerosol carriers
US5849263A (en) * 1993-03-30 1998-12-15 Charlotte-Mecklenburg Hospital Authority Pharmaceutical compositions containing alkylaryl polyether alcohol polymer
TW402506B (en) * 1993-06-24 2000-08-21 Astra Ab Therapeutic preparation for inhalation
DE4425255A1 (de) * 1994-07-16 1996-01-18 Asta Medica Ag Formulierung zur inhalativen Applikation
AR002009A1 (es) * 1994-12-22 1998-01-07 Astra Ab Composicion farmaceutica, procedimiento para la manufactura de un polvo de proliposoma como el utilizado en dicha composicion, procedimiento para lamanufactura de dicha composicion, uso de dicha composicion farmaceutica en la manufactura de un medicamento y dispositivo inhalador de polvo seco.
US5612053A (en) * 1995-04-07 1997-03-18 Edward Mendell Co., Inc. Controlled release insufflation carrier for medicaments
US5690374A (en) * 1996-04-19 1997-11-25 Nor-Easter Enterprises, Inc. Shock-absorbing tool handle
US6613795B2 (en) 1996-11-11 2003-09-02 Christian Noe Enantiomerically pure basic arylcycloalkylhydroxycarboxylic esters, processes for their preparation and their use in medicaments
ES2195121T3 (es) 1996-11-11 2003-12-01 Christian R Noe Uso de una sal farmaceuticamente aceptable de (3r,2'r)-3-((ciclopentilhidroxifenilacetil)oxi)-1,1-dimetilpirrolidinio para la preparacion de un medicamento.
PT954282E (pt) * 1997-01-16 2005-06-30 Massachusetts Inst Technology Preparacao de particulas para inalacao
SE9700133D0 (sv) * 1997-01-20 1997-01-20 Astra Ab New formulation
EP1014943B1 (de) * 1997-02-05 2002-06-19 Jago Research Ag Medizinische aerosolformulierungen
US6495167B2 (en) * 1997-03-20 2002-12-17 Schering Corporation Preparation of powder agglomerates
ES2234266T3 (es) * 1998-07-24 2005-06-16 Jago Research Ag Formulaciones medicas para aerosoles.
CN1150890C (zh) * 1998-08-04 2004-05-26 杰格研究股份公司 药用气溶胶制剂
NZ511527A (en) * 1998-11-13 2002-10-25 Jago Res A Dry powder for inhalation
US6406745B1 (en) * 1999-06-07 2002-06-18 Nanosphere, Inc. Methods for coating particles and particles produced thereby
WO2001008681A1 (en) * 1999-08-02 2001-02-08 First Horizon Pharmaceutical Corporation Methods of administration of glycopyrrolate compositions
GB0008660D0 (en) 2000-04-07 2000-05-31 Arakis Ltd The treatment of respiratory diseases
US6758795B2 (en) * 2000-08-22 2004-07-06 Stephen Barber Adjustable water-fillable exercise weights
GB0029903D0 (en) * 2000-12-07 2001-01-24 Arakis Ltd Use of anti-muscarinic agents
GB0410398D0 (en) * 2004-05-10 2004-06-16 Arakis Ltd The treatment of respiratory disease
GB0410399D0 (en) * 2004-05-10 2004-06-16 Arakis Ltd The treatment of respiratory disease
TWI509631B (zh) 2011-02-25 2015-11-21 漢高智慧財產控股公司 用於電子裝置之可燒結銀薄片黏著劑

Also Published As

Publication number Publication date
EP1449528A1 (en) 2004-08-25
US20030068280A1 (en) 2003-04-10
EP1267866A2 (en) 2003-01-02
NO336142B1 (no) 2015-05-26
NO20024708L (no) 2002-10-24
BR0109875A (pt) 2004-07-20
ES2687751T3 (es) 2018-10-29
AU8930601A (en) 2001-10-23
US20050019271A1 (en) 2005-01-27
US7368104B2 (en) 2008-05-06
ATE330585T2 (de) 2006-07-15
AU2004242450A1 (en) 2005-01-20
DE60120936T2 (de) 2006-11-02
AU776913B2 (en) 2004-09-23
CY1105120T1 (el) 2010-03-03
NO2015024I2 (no) 2015-11-25
WO2001076575A3 (en) 2002-03-28
HK1050846A1 (en) 2003-07-11
JP2003530344A (ja) 2003-10-14
NO2015024I1 (no) 2015-11-25
ZA200207420B (en) 2003-09-16
AU2010200660A1 (en) 2010-03-11
EP1267866B1 (en) 2006-06-21
LU92393I2 (fr) 2015-11-02
EP1267866B2 (en) 2016-07-20
NO20024708D0 (no) 2002-10-01
HUP0301518A2 (hu) 2003-08-28
JP5042426B2 (ja) 2012-10-03
GB0008660D0 (en) 2000-05-31
MXPA02009718A (es) 2003-05-27
US20080220073A1 (en) 2008-09-11
DK1267866T4 (en) 2016-10-03
WO2001076575A2 (en) 2001-10-18
ES2266242T5 (es) 2016-10-04
CN1422154A (zh) 2003-06-04
IL151791A (en) 2015-05-31
EP1449528B1 (en) 2018-08-08
CN101181263B (zh) 2011-07-06
EP2193791A1 (en) 2010-06-09
LU92166I2 (fr) 2014-03-13
PL364024A1 (en) 2004-11-29
AU2010200660B2 (en) 2012-04-19
DE60120936D1 (de) 2006-08-03
CA2405705C (en) 2011-06-07
DK1267866T3 (da) 2006-10-23
HU230958B1 (hu) 2019-06-28
DE60120936T3 (de) 2016-11-17
CN1292745C (zh) 2007-01-03
AU2004242450B2 (en) 2010-06-03
HK1050846B (en) 2007-01-26
HUS1900056I1 (hu) 2020-02-28
NO2015025I1 (no) 2015-12-07
US7229607B2 (en) 2007-06-12
NZ521476A (en) 2004-10-29
BE2013C023I2 (OSRAM) 2020-06-24
CN1720995A (zh) 2006-01-18
PT1267866E (pt) 2006-10-31
CN101181263A (zh) 2008-05-21
CA2405705A1 (en) 2001-10-18
IL151791A0 (en) 2003-04-10
ES2266242T3 (es) 2007-03-01
US8029768B2 (en) 2011-10-04

Similar Documents

Publication Publication Date Title
NZ535284A (en) Microparticles of glycopyrrolate for the treatment of respiratory diseases
MY129384A (en) "pharmaceutical formulations for dry powder inhalers in the form of hard-pellets"
CA2304819A1 (en) Perforated microparticles and methods of use
ATE363892T1 (de) Verbesserte pulverformulierungen zur inhalation
JP2002529396A5 (OSRAM)
Yang et al. Drug delivery performance of the mometasone furoate dry powder inhaler
JO3102B1 (ar) صيغ صيدلانية لوسائل استنشاق بها مسحوق جاف تشتمل على مكون فعال بقوة منخفضة الجرعة
WO2006008517A3 (en) Use of dry powder compositions for pulmonary delivery
ATE219942T1 (de) Therapeutische pulverformulierung zur pulmonaren anwendung, welche kristallines insulin enthält
MXPA05009629A (es) Composiciones que contienen trospio.
ATE402727T1 (de) Pulverinhalator
TW200602054A (en) Use of compounds in a dry powder inhaler
EE03950B1 (et) Inhaleeritav terbutaliinsulfaati sisaldav ravimvorm puistetihedusega 0,28 kuni 0,38 g/ml, meetod selle valmistamiseks ja kasutamine
PL365736A1 (en) Bimodal dry powder formulation for inhalation
TH75699A (th) สูตรผสมทางเภสัชกรรมสำหรับเครื่องพ่นยาผงแห้ง ซึ่งประกอบรวมด้วยส่วนประกอบออกฤทธิ์ที่มีความแรงของขนาดยาต่ำ
GEP20022782B (en) Perforated Microparticles, Methods of Their Production, Their Use for Production of Aerosol Medikaments

Legal Events

Date Code Title Description
RENW Renewal (renewal fees accepted)
PSEA Patent sealed
RENW Renewal (renewal fees accepted)
RENW Renewal (renewal fees accepted)
RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 7 YEARS UNTIL 09 APR 2021 BY LEA

Effective date: 20140402

ASS Change of ownership

Owner name: HEPTARES THERAPEUTICS LIMITED, GB

Effective date: 20190118

EXPY Patent expired